NCT05691504 - Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions

Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube CarcinomaMetastatic Platinum-Resistant Ovarian CarcinomaMetastatic Primary Peritoneal CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood

DRUG

Cobimetinib

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Pelcitoclax

Given IV

Trial Locations (6)

20892

ACTIVE_NOT_RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

ACTIVE_NOT_RECRUITING

National Institutes of Health Clinical Center, Bethesda

21287

RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH